Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Advances in Microarray Technology Conference

By Biotechdaily staff writers
Posted on 07 Jun 2007
The latest Advances in Microarray Technology (AMT) Conference, held in conjunction with the Lab-on-a-Chip World Congress, highlighted the movement of the fields from the research lab into diagnostics. More...
The conferences were held at the Herriot Watt University in Edinburgh (Scotland, UK) in May 2007, and were organized by Select Biosciences (Shelton, CT, USA).

Many presentations focused on developing methodologies and techniques for research analysis, while others were focused on using those techniques in a diagnostic setting. A lot of companies are looking at microarrays as a platform for molecular diagnostics, said Ken Browne, managing director of Select Biosciences.

Dr. Steven Bodovitz, of the biotechnology and pharmaceutical strategy consulting company Bioperspectives (San Francisco, CA, USA; www.bioperspectives.com) spoke about applications such as array-based comparative genomic hybridization (aCGH) chromatin immunoprecipitation on microarray (ChIP on chip), single nucleotide polymorphism (SNP) profiling, and microRNA (miRNA) profiling as important growth drivers.

In the '80s, there was lots of excitement in using microarrays to look for drug targets, which didn't really work with any regularity, but as the technology has matured, more mature applications such as diagnostics have started to emerge, said Dr. Bodovitz.

Mr. Browne believes this parallels the industry's increased interest in diagnostics with Siemens Medical Solutions (Erlangen, Germany), Philips Medical Systems (Best, Nederlands), and CombiMatrix (Mukilteo, WA, USA), making significant attempts to strengthen their presence in the sector.

Microarray-based diagnostic devices may not only be able to increase the speed of disease diagnosis, but may also be able to help track patients response to drugs in clinical trials and also be used as tests to develop personalized medicine.

The increasing interest in using microarrays in diagnostic devices (often in conjunction with microfluidic devices) may be ascribed to the increasingly consistent data generated by the arrays. Microarrays are now more heavily regulated in terms of the bioinformatics, which has led to more credible results being generated than when people were doing their own thing and publishing results that were very difficult to reproduce, continued Mr. Browne.

This year, the conference had more than 40 exhibitors, a number which has been growing at about 30% a year since the conference's started three years ago.


Related Links:
Herriot Watt University
Select Biosciences
Bioperspectives

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.